Compare Amphastar Pharmaceuticals Inc (AMPH) vs Huntington Ingalls Industries Inc (HII) Price & Performance

AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.

Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.

HII trades at $324.48, up 0.85% on the day, with a bullish technical signal driven by moving averages and recent contract wins. The company reported strong Q2 2026 results, beating EPS estimates with $5.27 versus $3.79 expected, and revenue growth of 10.9%. Key developments include a $900 million robotics partnership and new submarine contracts, supporting a positive outlook.

The stock offers upside to the consensus price target of $359.67, with 44% of analysts rating it Buy. Risks include execution challenges in shipbuilding and political headwinds. Fundamentals are solid with a P/E of 19.7 and ROE of 12.97%, but overbought RSI levels near 85.92 suggest near-term caution.